Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors

Figure 4

Differential PG expression correlates with clinical outcome. Survival and probability curves for the following correlations: (a) loco-regional relapse vs de novo expression of NG2/CSPG4, (b) loco-regional relapse vs T group classification; (c) loco-regional relapse vs coincident NG2/CSPG4 expression and advanced T classification; (d) lymphnodal metastases vs enhanced SDC2 expression in stromal cells; (e) lymphnodal metastases vs manifestation of precancerous lesions; (f) lymphnodal metastases vs the combination of both previous prognostic indicators; (g) distant metastases vs up-regulated SDC1 expression; (h) distant metastases vs infiltration of cervical lymph nodes; (i) distant metastases vs the combination of both previous prognostic indicators; (j) overall survival vs enhanced SDC2 expression in the stromal compartment; (k) overall survival vs N classification; (l) overall survival vs the coincidence of both previously indicated events; (m) the occurrence of any of the clinical outcomes vs up-regulated SDC1 expression; (n) the occurrence of any of the clinical outcomes vs N classification; (o) the occurrence of any of the clinical outcomes vs the combination of both above listed events; (p) overall survival, (q) distant metastases and (r) the occurrence of any of the clinical outcomes vs the combination of SDC1 up-regulation, de novo expression of NG2/CSPG4 and stromal enhancement of SDC2 positivity. Abbreviations: LRFS, loco-regional relapse-free survival; LMFS, lymphnodal metastasis-free survival; DMFS, distant metastasis-free survival; OS, overall survival, COsFS, clinical outcomes-free survival.

Back to article page